BLUETTI: Choosing the Best Solar Battery for a Solar System
28.7.2023 09:52:00 EEST | Business Wire | Press release
Many homeowners install solar panels on their roofs to gain free renewable energy. But having a solar panel system isn't a sure thing when power outages occur at night or on rainy days.
Investing in a solar battery will allow excess solar power to be stored for later use instead of being wasted. There will be enough free power in storage for emergencies or peak hours.
Common Types of Batteries for Solar Systems
Lead-Acid Batteries
Lead-Acid batteries have been in use for a long time and are relatively affordable. They offer high surge currents and have a relatively high energy density. Yet, they have a shorter lifespan and require regular maintenance.
Nickel-Cadmium Batteries
Nickel-cadmium batteries are known for their durability and ability to withstand extreme temperatures. They have a long lifespan and high efficiency of charge/discharge.
Lithium-Ion Batteries
Lithium-ion batteries are lightweight, require minimal maintenance, and offer high energy density. Two main lithium-ion types, lithium nickel manganese cobalt oxide (NMC) and lithium iron phosphate (LFP), are the most popular for solar energy storage.
Why Choose a LiFePO4 Battery?
LiFePO4 batteries stand out as a favorable option for solar system owners with added safety, stability, and a long life span of up to 3.500 cycles.
Some of the Top LiFePO4 Battery Solutions
Aside from the inherent benefits of LiFePO4 batteries, BLUETTI battery systems offer some outstanding features, including the self-heating function to ensure smooth operation at temperatures as low as -20° C (-4° F), UPS function, and wide compatibility with existing or new solar systems.
For Residential Solar Systems
The BLUETTI EP600&B500 and AC500&B300S modular battery systems are perfect for rooftop solar systems that typically require more storage capacity. With flexible capacities ranging from 9.920Wh to 39.680Wh for the EP600, or from 3.072Wh to 18.432Wh for the AC500, anyone can customize their battery system by adding batteries as needed.
For Balcony/RV Solar Systems
Balcony and RV solar systems typically have smaller solar arrays for partial utility independence. BLUETTI's all-in-one AC200P or modular AC300 battery systems are designed for these setups. These batteries are compact, moveable, and provide 3.000W or 2.000W power to various devices.
About BLUETTI
BLUETTI has been committed to promoting sustainability and green energy solutions since its inception. This commitment to sustainable energy has helped BLUETTI expand its reach to over 100 countries and gain the trust of millions of customers worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727628920/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results13.5.2026 09:38:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER). Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth. Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amortization expenses for VYVANSE and lower restructuring expenses. Core EPS increased by 5.2% YoY at AER and by 3.1% at CER, while reported EPS increased by 78.1% YoY. Adjusted Fre
Allianz Delivers Record Operating Profit in Strong Start to 202613.5.2026 08:20:00 EEST | Press release
1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net income advances by 48.4 percent to 3.8 billion euros, impacted by the sale of the stakes in our Indian Joint Ventures. Underlying growth, which adjusts for the sale effects and offsetting measures, is strong at 7 percent2Core earnings per share grow 50.7 percent and reach 9.96 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 9 percent 2Annualized core RoE at 24.2 percent, underlying level very strong at 18 percent 2Solvency IIratio3 increases by 2 percentage points to 221 percent4. Capital generation was st
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca13.5.2026 08:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca’s IT infrastructure and decision workflows. The new agents' functionality is intended to help AstraZeneca’s decision-making teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis within established governance, security, and enterprise standards. "At Owkin, we believe the future of the pharmaceutical industry is agentic," said Thomas Clozel, CEO and co-founder of Owkin. "Our exper
Abu Dhabi's Phoenix Group Partners with DC Max to Unlock $8 Billion European AI Data Center Opportunity, with Lyon, France as First Deployment13.5.2026 08:00:00 EEST | Press release
Phoenix Group PLC (ADX: PHX), an IHC portfolio company and global digital infrastructure operator, today announced a strategic partnership with DC Max to develop its first European AI data center, an 18MW facility in Lyon, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512531777/en/ From left to right: Matthias Luecker, Chairman of DC Max, and Munaf Ali, Co-Founder and Group CEO of Phoenix Group, during the signing ceremony for the strategic partnership between Phoenix Group and DC Max to launch a European AI infrastructure platform anchored by the company’s first deployment in Lyon, France. (Photo: AETOSWire) The project is the inaugural deployment of Phoenix's European Data Center Platform, a scalable framework targeting over 1GW of combined AI and HPC capacity across Europe and the GCC. Phoenix sees this move as a direct extension of the UAE’s national AI ambition, an Abu Dhabi-headquartered company bringing it
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim12.5.2026 20:39:00 EEST | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. “We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents,” said Dr. Arno Riße, Angel’s attorney at the Arnold Ruess law firm of Düsseldorf. “We are grateful that the court decided not to grant Align's request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.” “We categorically deny the allegations of i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom